阿米巴病市場規模、佔有率和成長分析：按療法、劑型、通路、最終用戶和地區分類－2026-2033年產業預測

2024 年全球阿米巴病市場價值為 3.825 億美元，預計到 2025 年將成長至 4.0055 億美元，到 2033 年將成長至 5.824 億美元，在預測期（2026-2033 年）內複合年成長率為 4.72%。

全球阿米巴病市場涵蓋了溶組織內阿米巴（Entamoeba histolytica）的診斷、治療和預防措施，溶組織內阿米巴是貧困階級腹瀉的主要病因之一。由於其對健康的嚴重影響，包括可能導致死亡，阿米巴病給衛生條件堪憂的醫療衛生系統帶來了沉重的經濟負擔。近年來，人們對無症狀攜帶者的認知不斷提高，以及對快速治療的需求日益成長，促使檢測方法從傳統的顯微鏡檢查轉向抗原檢測和聚合酶鍊式反應（PCR）等先進技術。東南亞地區即時層析法試劑盒等創新技術的出現，擴大了檢測範圍，並展現了技術在市場擴張中的作用。此外，各國政府加大對水、環境衛生和個人衛生（WASH）計畫的投入，也推動了對診斷和治療解決方案的需求，並為採用多重檢測板進行全面篩檢鋪平了道路。

全球阿米巴病市場成長要素

全球阿米巴病市場成長的主要驅動力是公眾對該疾病症狀和傳播途徑的認知不斷提高。這種認知的提升促使更多人及時就醫，從而有助於早期發現和治療。這反過來又可以減輕疾病的嚴重程度並預防併發症。隨著醫療專業人員對阿米巴病的了解不斷加深，並將其積極納入鑑別診斷，實際病例的發現率也不斷提高。因此，診斷活動的活性化推動了對診斷試劑盒、抗寄生蟲藥物和相關醫療服務的需求，進一步促進了全球阿米巴病市場的擴張。

全球阿米巴病市場的限制因素

由於許多低收入國家普遍存在醫療基礎設施不足的問題，全球阿米巴病市場面臨嚴峻的限制。這種限制阻礙了患者獲得先進的阿米巴病治療方案，這些方案往往難以取得。因此，這些地區往往依賴過時且療效欠佳的療法，而地理和物流方面的挑戰又加劇了供應不穩定的問題。此外，這些地區的醫護人員常常缺乏有效實施新治療方案所需的訓練和資源。因此，患者的治療效果仍不盡人意，許多高需求地區的創新療法研發也基本上停滯不前。

全球阿米巴病市場趨勢

全球阿米巴病市場正經歷一場重大變革，而即時檢測（POC​​T）的快速普及正是推動這項變革的主要動力。這一趨勢正在提升都市區急診環境下的診斷能力，使臨床醫生能夠快速識別阿米巴病並啟動治療，而無需過度依賴中心檢查室。隨著各國政府和非政府組織優先發展分散式醫療解決方案，對便捷可靠的診斷工具的需求日益成長。製造商正積極響應這項需求，開發操作簡單、只需極少培訓且能在各種氣候條件下有效運作的診斷工具。這項轉變不僅將為患者提供更多及時治療的機會，也將協助全球對抗阿米巴病的各項衛生舉措。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球阿米巴病市場規模：依治療方法分類

• 甲硝唑
• 替硝唑
• Paromomycin
• 二氯尼特

全球阿米巴病市場規模：以劑型分類

• 口服
• 靜脈

全球阿米巴病市場規模：按通路分類

• 醫院藥房
• 零售藥房
• 政府衛生計劃

全球阿米巴病市場規模：依最終用戶分類

• 醫院
• 公共衛生診所
• 旅遊醫學診所

全球阿米巴病市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer Inc.
• Sanofi SA
• GlaxoSmithKline
• Cipla Ltd.
• Sun Pharmaceutical
• Mylan（Viatris）
• Teva Pharmaceutical
• Dr. Reddy's Laboratories
• Cadila Healthcare（Zydus）
• Aurobindo Pharma
• Lupin Limited
• Hikma Pharmaceuticals
• Mankind Pharma
• Macleods Pharmaceuticals
• Searle Company
• Square Pharmaceuticals
• Beximco Pharmaceuticals
• Strides Pharma Science
• Indoco Remedies
• Alembic Pharmaceuticals

結論與建議

Global Amebiasis Market size was valued at USD 382.50 Million in 2024 and is poised to grow from USD 400.55 Million in 2025 to USD 582.40 Million by 2033, growing at a CAGR of 4.72% during the forecast period (2026-2033).

The global amebiasis market encompasses diagnostics, therapeutics, and prevention methods targeting Entamoeba histolytica, a leading cause of diarrhea in underprivileged populations. Due to its serious health implications, including potential mortality, amebiasis imposes a considerable financial strain on healthcare systems struggling with sanitation issues. Recent years have seen a shift from traditional microscopy to advanced techniques like antigen detection and PCR, driven by heightened awareness of asymptomatic carriers and the need for prompt treatment access. Innovations such as point-of-care immunochromatographic kits in Southeast Asia have broadened testing reach, demonstrating technology's role in market expansion. Additionally, increased governmental investment in water, sanitation, and hygiene initiatives is boosting demand for diagnostic and therapeutic solutions, paving the way for the adoption of multiplex panels for comprehensive screening.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amebiasis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Amebiasis Market Segments Analysis

Global amebiasis market is segmented by treatment, form, distribution, end-user and region. Based on treatment, the market is segmented into metronidazole, tinidazole, paromomycin and diloxanide furoate. Based on form, the market is segmented into oral and intravenous. Based on distribution, the market is segmented into hospital pharmacies, retail pharmacies and government health programs. Based on end-user, the market is segmented into hospitals, public health clinics and travel medicine clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Amebiasis Market

The growth of the global amebiasis market is significantly influenced by heightened public awareness surrounding the symptoms and transmission of the disease. This awareness encourages more individuals to seek medical attention promptly, facilitating early detection and treatment, which can reduce the severity of the illness and prevent complications. As healthcare professionals become more knowledgeable and inclusive of amebiasis in their differential diagnoses, there is an increase in the recognition of actual cases. Consequently, this uptick in diagnostic activity drives demand for diagnostic kits, antiparasitic medications, and related healthcare services, further bolstering the expansion of the amebiasis market worldwide.

Restraints in the Global Amebiasis Market

The global amebiasis market faces significant constraints due to the inadequate healthcare infrastructure prevalent in numerous low-income countries. This limitation hinders access to advanced amebiasis treatments, which are often unavailable. Consequently, these regions tend to rely on outdated and less effective therapy regimens, exacerbated by geographic and logistical challenges that disrupt consistent supply availability. Additionally, healthcare providers in these areas frequently lack the necessary training and resources to implement newer treatment protocols effectively. As a result of these obstacles, patient outcomes remain suboptimal, and there is minimal growth in the development of innovative therapies in many high-need regions globally.

Market Trends of the Global Amebiasis Market

The Global Amebiasis market is witnessing a significant transformation driven by the rapid adoption of point-of-care testing (POCT). This trend enhances diagnostic capabilities in both urban and rural emergency settings, allowing clinicians to quickly identify amebiasis and initiate treatment without relying heavily on central laboratories. As governments and NGOs prioritize decentralized healthcare solutions, the demand for user-friendly and stable diagnostic tools is rising. Manufacturers are responding by developing easy-to-use diagnostics that require minimal training and can function effectively in diverse climates. This shift not only improves patient access to timely treatment but also supports global health initiatives against amebiasis.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Amebiasis Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Metronidazole
• Tinidazole
• Paromomycin
• Diloxanide Furoate

Global Amebiasis Market Size by Form & CAGR (2026-2033)

• Market Overview
• Oral
• Intravenous

Global Amebiasis Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Government Health Programs

Global Amebiasis Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Public Health Clinics
• Travel Medicine Clinics

Global Amebiasis Market Size & CAGR (2026-2033)

• North America (Treatment, Form, Distribution, End-User)
  • US
  • Canada
• Europe (Treatment, Form, Distribution, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Form, Distribution, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Form, Distribution, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Form, Distribution, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cadila Healthcare (Zydus)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mankind Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Macleods Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Searle Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Square Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beximco Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strides Pharma Science
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indoco Remedies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations